Home > Quotes > AGN

Allergan, Inc. Stock Quote & Summary Data

AGN 
$179.25
*  
1.76
0.99%
Get AGN Alerts
*Delayed - data as of Oct. 20, 2014  -  Find a broker to begin trading AGN now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
1 Year Target: 200
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today's trading to the average daily volume. 2,231,455
Previous Close: $ 177.49
52 Week High /Low: $ 192.98 / $ 88.34
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 53,270,197,763
P/E Ratio: 42.08
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 28.73
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ 4.26
Annualized dividend $ 0.20
Ex Dividend Date Aug. 13, 2014
Dividend Payment Date Sep. 5, 2014
Current Yield 0.11 %
Beta 1.17

Intraday Chart

ETFs with AGN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
7.32% IQ Merger Arbitrage ETF (MNA) +0.04  (0.15%)
5.02% iShares U.S. Pharmaceutical ETF (IHE) +5.27  (4.06%)
4.52% Merrill Lynch Pharmaceutical HOLDRS (PPH) -0.33  (-0.55%)
4.02% iShares MSCI Netherlands Index Fund (EWN) -3.11  (-12.10%)
2.31% iShares MSCI USA Momentum Factor ETF (MTUM) -0.26  (-0.42%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a multi-specialty health care company focused on developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential - to see more clearly, move more freely and express themselves more fully. We discover, develop and commercialize a diverse range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets in more than 100 countries around the world. We are also a pioneer in specialty pharmaceutical, biologic and medical device research and development. Our research and development efforts are focused on products and technologies related to the many specialty areas in which we currently operate as well as new specialty areas where unmet medical needs are significant. In 2013, our research and development expenditures were approximately 16.  ... More ...  

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?